PD-L1 | CancerGRACE

Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

Article

Dr. David Spigel from Sarah Cannon Cancer Center offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.

[powerpress]

Read more about Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?

Immunotherapies in Lung Cancer, Part 2: Dr. Brahmer on Ipilumumab, Anti-PD1, Anticancer Viruses, and Talactoferrin

Video

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?". Our

Read more about Immunotherapies in Lung Cancer, Part 2: Dr. Brahmer on Ipilumumab, Anti-PD1, Anticancer Viruses, and Talactoferrin
2 comments

Subscribe to PD-L1